---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-037371"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2026-09-23T10:03:20+00:00"
generated_at: "2026-09-23T10:05:19.095922+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ionis and Roche report positive Phase 3 interim data for sefaxersen in IgAN

## Summary
- Phase 3 IMAgINATION met primary endpoint: sefaxersen reduced proteinuria (UPCR) vs placebo at 37 weeks, statistically significant and clinically meaningful.
- Safety consistent with prior data, no new signals; study continues blinded to week 105 eGFR assessment.
- 459 patients enrolled, randomized 1:1; sefaxersen is once-monthly subcutaneous self-administered injection.
- Interim data to be presented at medical meeting and shared with health authorities to expedite potential approval.
- Ionis eligible for regulatory/sales milestones and tiered royalties on net sales from Roche license.

## SEC filing metadata
- accession: 0001140361-26-037371
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2026-09-23T10:03:20+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036126037371/0001140361-26-037371-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036126037371/ef20082626_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-037371
- JSON: https://secwatch.observer/filing/0001140361-26-037371.json
- Plain text: https://secwatch.observer/filing/0001140361-26-037371.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.